C.T. de Wit Graduate School for Production Ecology and Resource Conservation · NL
Area of research
Cancer Research · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Genetic factors in colorectal cancer, and Colorectal Cancer Treatments and Studies.
Genomic profile of advanced breast cancer in circulating tumour DNA
Author Correction: Genomic profile of advanced breast cancer in circulating tumor DNA
Abstract PS5-02: Assessment of early ctDNA dynamics to predict efficacy of targeted therapies in metastatic breast cancer: Results from plasmaMATCH trial
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations
Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients
Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion <i>BRCA</i> Mutations among Patients with Advanced Solid Tumors
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel
Resistance to TRK inhibition mediated by convergent MAPK pathway activation
Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors
Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer
Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer
BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale
Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations
Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancer
Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study
Identification of Actionable Fusions as an Anti-EGFR Resistance Mechanism Using a Circulating Tumor DNA Assay
Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine
Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i> -Amplified Esophagogastric Cancer
Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for <i>EGFR</i> -Amplified Gastroesophageal Adenocarcinoma
Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients
Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA
Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma
Preoperative Circulating Tumor DNA in Patients with Peritoneal Carcinomatosis is an Independent Predictor of Progression-Free Survival
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer